September 9, 2021Open Access

Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease

YWYinlian WuFujian Medical University RKRahul KumarChangi General Hospital MWMing-Fang WangFujian Medical University

Key Points

Key points are not available for this paper at this time.

Abstract

APRI and BARD scores do not perform well in MAFLD. The FIB-4 and NFS could be more useful, but a new threshold is needed. Novel non-invasive scoring systems for fibrosis are required for MAFLD.

KI fragen

Bookmark

View Full Paper

Cite This Study

Wu et al. (Thu,) studied this question.

synapsesocial.com/papers/69d94bd626e251a019684152 https://doi.org/https://doi.org/10.3748/wjg.v27.i34.5753

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C2003 · 4,377 citations
2Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease2015 · 2,962 citations
3Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study2018 · 1,744 citations
4An Algorithm for the Grading of Activity in Chronic Hepatitis C1996 · 4,025 citations
5Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease2010 · 949 citations

KI fragen

Bookmark

View Full Paper